ANDAINJECTIONINJECTABLE
Approved
Nov 2020
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NOREPINEPHRINE BITARTRATE (norepinephrine bitartrate) by Fresenius Kabi is (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action). First approved in 2020.
Drug data last refreshed 19h ago
Mechanism of Action
(alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on NOREPINEPHRINE BITARTRATE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.